Vincerx Pharma, Inc. (VINC)
NASDAQ: VINC · Real-Time Price · USD
0.2756
-0.2674 (-49.24%)
At close: Apr 9, 2025, 4:00 PM
0.2700
-0.0056 (-2.04%)
Pre-market: Apr 10, 2025, 9:17 AM EDT
Vincerx Pharma Employees
As of December 31, 2024, Vincerx Pharma had 13 total employees, including 12 full-time and 1 part-time employees. The number of employees decreased by 29 or -69.05% compared to the previous year.
Employees
13
Change (1Y)
-29
Growth (1Y)
-69.05%
Revenue / Employee
n/a
Profits / Employee
-$2,313,385
Market Cap
1.44M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 13 | -29 | -69.05% |
Dec 31, 2023 | 42 | 1 | 2.44% |
Dec 31, 2022 | 41 | -15 | -26.79% |
Dec 31, 2021 | 56 | 28 | 100.00% |
Dec 31, 2020 | 28 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VINC News
- 1 day ago - Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities - GlobeNewsWire
- 23 days ago - Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI - GlobeNewsWire
- 5 weeks ago - Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - GlobeNewsWire
- 2 months ago - Vincerx Pharma, Inc. Announces Reverse Stock Split - GlobeNewsWire
- 3 months ago - VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC - Business Wire
- 3 months ago - Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - GlobeNewsWire
- 4 months ago - Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 - GlobeNewsWire
- 6 months ago - Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates - Benzinga